SCHEMBL4848044

SCHEMBL4848044

Cc1oc(-c2ccco2)nc1COc1ccc(COc2nn(Cc3ccccc3)cc2CO)cc1-c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.42
PPARG P37231 7/20 0.39
KDM4E B2RXH2 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
HPGD P15428 2/20 0.38
TSHR P16473 2/20 0.38
HSD17B10 Q99714 2/20 0.38
FFAR1 O14842 1/20 0.35
PTGER1 P34995 2/20 0.35
LMNA P02545 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
ALOX15 P16050 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PPARA Q07869 6/20 0.34
USP2 O75604 1/20 0.33
MAPK1 P28482 1/20 0.33
ADORA2A P29274 1/20 0.33
DRD2 P14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4848210 0.93 PPARG (0.44) KDRPPARGKDM4ESMN1; SMN2ALDH1A1
SCHEMBL4855201 0.92 PPARG (0.40) KDRPPARGKDM4ESMN1; SMN2ALDH1A1
SCHEMBL4850476 0.92 PPARG (0.46) KDRPPARGKDM4ESMN1; SMN2ALDH1A1
SCHEMBL4855315 0.92 PPARG (0.40) KDRPPARGKDM4ESMN1; SMN2ALDH1A1
SCHEMBL4850393 0.92 PPARG (0.40) KDRPPARGKDM4ESMN1; SMN2ALDH1A1
SCHEMBL4852288 0.91 PPARG (0.49) KDRPPARGKDM4ESMN1; SMN2ALDH1A1
SCHEMBL4846894 0.91 PPARG (0.41) KDRPPARGKDM4ESMN1; SMN2ALDH1A1
SCHEMBL4845989 0.91 KDM4E (0.43) KDRPPARGKDM4ESMN1; SMN2ALDH1A1
SCHEMBL4852132 0.90 PPARG (0.40) KDRPPARGKDM4ESMN1; SMN2ALDH1A1
SCHEMBL4844070 0.90 PPARG (0.43) KDRPPARGKDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 KDR 2335/4885PPARG 536/4885KDM4E 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.